[TITLE]United Kingdom Healthcare Market Databook Q2 2025: 300+ KPIs Covering Healthcare Infrastructure, Patient Demographics, Diagnostics, Public and Private Spending, Clinical and Non-Clinical Workforce:
[TEXT]
Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "United Kingdom Healthcare Industry
[Source link]: https://www.globenewswire.com/news-release/2025/10/01/3159750/28124/en/United-Kingdom-Healthcare-Market-Databook-Q2-2025-300-KPIs-Covering-Healthcare-Infrastructure-Patient-Demographics-Diagnostics-Public-and-Private-Spending-Clinical-and-Non-Clinical.html


===== Company info for companies mentioned in news =====

Company name: none
name: none
symbol: None
note: no reliable listing found
------------------------------------------------------------------

================================================================================

[TITLE]United Kingdom Healthcare Market Databook Q2 2025: 300+ KPIs Covering Healthcare Infrastructure, Patient Demographics, Diagnostics, Public and Private Spending, Clinical and Non-Clinical Workforce:
[TEXT]
Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "United Kingdom Healthcare Industry
[Source link]: https://www.globenewswire.com/news-release/2025/10/01/3159750/28124/en/United-Kingdom-Healthcare-Market-Databook-Q2-2025-300-KPIs-Covering-Healthcare-Infrastructure-Patient-Demographics-Diagnostics-Public-and-Private-Spending-Clinical-and-Non-Clinical.html


No companies mentioned in this section

================================================================================

[TITLE]ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®:
[TEXT]
Initial $100 million term loan to propel market share growth in the U.S.

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced it has entered into a senior secured term loan facility of up to $250 million with an affiliate of RA Capital Management (RA Capital), the company’s largest shareholder, and an affiliate of OMERS Life Sciences as lenders.

ARS Pharma has borrowed an initial $100 million, which will be used primarily to accelerate neffy’s commercial growth. The funding will also support marketing and medical affairs initiatives to generate and disseminate real-world evidence
[Source link]: https://www.globenewswire.com/news-release/2025/09/29/3158104/0/en/ARS-Pharmaceuticals-Secures-Up-to-250-Million-Loan-Facility-with-RA-Capital-Management-and-OMERS-Life-Sciences-to-Accelerate-U-S-Commercialization-of-neffy.html


[TITLE]Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation:
[TEXT]
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (“Titan” or “TTNP”) today announced the successful closing of its previously announced merger with Black Titan Corporation (“Black Titan”) and TalenTec Sdn. Bhd. (“TalenTec”). Following the merger, the combined company's ordinary shares, $0.0001 par value per share, will trade on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC.

Pursuant to the Merger and Contribution and Share Exchange Agreement dated August 19, 2024, Titan has become a wholly owned subsidiary of Black Titan Corporation, effective as of October 1, 2025.

As part of the transaction, each issued and outstanding share of Titan common stock was automatically converted into ordinary shares of Black Titan on a one-for-one basis. Trading of Titan’s common stock on the Nasdaq Capital Market ceased trading at the close of business on October 1, 2025, and Black Titan’s ordinary shares commenced trading on Nasdaq on October 2, 2025.

Chay W. J., CEO of Black Titan, remarked, “This merger represents more than a structural change, it’s the beginning of a new chapter of innovation and global expansion. We are well-positioned to execute our strategic vision and bring transformative value to our stakeholders.”

ARC Group Ltd. acted as the exclusive financial advisor to Black Titan Corporation in connection with the transaction.
[Source link]: https://www.globenewswire.com/news-release/2025/10/03/3161232/0/en/Titan-Pharmaceuticals-Inc-Announces-Closing-of-Merger-with-Black-Titan-Corporation.html


[TITLE]Mira Pharmaceuticals closes acquisition of SKNY Pharmaceuticals MIRA:
[TEXT]
Tues

FRMI X FRMI Fermi America

IPO

Managers: UBS, Evercore ISI, Cantor Fitzgerald & Mizuho, Macquarie, Rothschild & Co Redburn, Stifel, Truist, Berenberg, Panmure Liberum

Priced at: $21.00

32.5M Shares

Special Comments

Exclusive Analysis Locked Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4205050/MIRA-Mira-Pharmaceuticals-closes-acquisition-of-SKNY-Pharmaceuticals


[TITLE]Patton Fund Management Inc. Invests $210,000 in Regeneron Pharmaceuticals, Inc. $REGN:
[TEXT]
Patton Fund Management Inc. purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 400 shares of the biopharmaceutical company’s stock, valued at approximately $210,000.

Other hedge funds have also bought and sold shares of the company. Marietta Wealth Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after purchasing an additional 2,501 shares in the last quarter. Sepio Capital LP boosted its holdings in Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 842 shares in the last quarter. Founders Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after acquiring an additional 538 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of Regeneron Pharmaceuticals by 9.4% during the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company’s stock valued at $94,779,000 after acquiring an additional 12,793 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Get Regeneron Pharmaceuticals alerts:

Analysts Set New Price Targets

REGN has been the topic of several recent analyst reports. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective on the stock. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research note on Monday, August 4th. Jefferies Financial Group raised their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Finally, JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research note on Monday, June 9th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Up 0.3%

Shares of Regeneron Pharmaceuticals stock opened at $562.27 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,061.60. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average is $570.12 and its 200 day moving average is $568.72. The company has a market cap of $59.59 billion, a price-to-earnings ratio of 14.17, a price-to-earnings-growth ratio of 1.79 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $11.56 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/10/01/patton-fund-management-inc-invests-210000-in-regeneron-pharmaceuticals-inc-regn/


===== Company info for companies mentioned in news =====

Company name: ars pharmaceuticals
symbol: SPRY
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759629097
name: ars pharmaceuticals
------------------------------------------------------------------

Company name: mira pharmaceuticals
symbol: MIRA
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759629098
name: mira pharmaceuticals
------------------------------------------------------------------

Company name: regeneron pharmaceuticals
symbol: REGN
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759629099
name: regeneron pharmaceuticals
------------------------------------------------------------------

Company name: titan pharmaceuticals
symbol: TTNP
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759629099
name: titan pharmaceuticals
------------------------------------------------------------------

================================================================================

[TITLE]SeaBridge Investment Advisors LLC Sells 1,675 Shares of iShares Biotechnology ETF $IBB:
[TEXT]
SeaBridge Investment Advisors LLC cut its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 29.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,015 shares of the financial services provider’s stock after selling 1,675 shares during the period. SeaBridge Investment Advisors LLC’s holdings in iShares Biotechnology ETF were worth $508,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of IBB. Moors & Cabot Inc. grew its position in iShares Biotechnology ETF by 2.0% during the 1st quarter. Moors & Cabot Inc. now owns 29,053 shares of the financial services provider’s stock worth $3,716,000 after acquiring an additional 558 shares during the last quarter. IFP Advisors Inc raised its position in iShares Biotechnology ETF by 23.9% in the first quarter. IFP Advisors Inc now owns 19,849 shares of the financial services provider’s stock valued at $2,539,000 after purchasing an additional 3,831 shares during the last quarter. N.E.W. Advisory Services LLC acquired a new stake in shares of iShares Biotechnology ETF during the first quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/28/seabridge-investment-advisors-llc-sells-1675-shares-of-ishares-biotechnology-etf-ibb/


===== Company info for companies mentioned in news =====

Company name: ishares biotechnology etf
name: ishares biotechnology etf
symbol: None
note: non-listable or generic entity
------------------------------------------------------------------

================================================================================

[TITLE]United Kingdom Healthcare Market Databook Q2 2025: 300+ KPIs Covering Healthcare Infrastructure, Patient Demographics, Diagnostics, Public and Private Spending, Clinical and Non-Clinical Workforce:
[TEXT]
Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "United Kingdom Healthcare Industry
[Source link]: https://www.globenewswire.com/news-release/2025/10/01/3159750/28124/en/United-Kingdom-Healthcare-Market-Databook-Q2-2025-300-KPIs-Covering-Healthcare-Infrastructure-Patient-Demographics-Diagnostics-Public-and-Private-Spending-Clinical-and-Non-Clinical.html


No companies mentioned in this section

================================================================================

